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Abstract
2-Methoxyestradiol (ME), one of the most widely investigated A-ring-modified metabolites of estrone, exerts significant anticancer activity
on numerous cancer cell lines. Its pharmacological actions, including cell cycle arrest, microtubule disruption and pro-apoptotic activity,
have already been described in detail. The currently tested D-ring-modified analogue of estrone, D-homoestrone, selectively inhibits cervi-
cal cancer cell proliferation and induces a G2/M phase cell cycle blockade, resulting in the development of apoptosis. The question arose
of whether the difference in the chemical structures of these analogues can influence the mechanism of anticancer action. The aim of
the present study was therefore to elucidate the molecular contributors of intracellular processes induced by D-homoestrone in HeLa
cells. Apoptosis triggered by D-homoestrone develops through activation of the intrinsic pathway, as demonstrated by determination of
the activities of caspase-8 and -9. It was revealed that D-homoestrone-treated HeLa cells are not able to enter mitosis because the cy-
clin-dependent kinase 1-cyclin B complex loses its activity, resulting in the decreased inactivation of stathmin and a concomitant distur-
bance of microtubule formation. However, unlike 2-ME, D-homoestrone does not exert a direct effect on tubulin polymerization. These
results led to the conclusion that the D-homoestrone-triggered intracellular processes resulting in a cell cycle arrest and apoptosis in
HeLa cells differ from those in the case of 2-ME. This may be regarded as an alternative mechanism of action among steroidal antican-
cer compounds.
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Introduction
The global burden of cancer is continuing to rise, largely because of
the ageing and growth of the world’s population and the increasing
adoption of cancer-causing behaviour, such as smoking and physical
inactivity, within economically developing countries. Cancer is the
second leading cause of death both worldwide and in economically
developed countries [1]. Among women, all types of tumours that
affect the reproductive organs (breast, uterus, cervix and ovaries) are
to be found in the list of the 10 most frequently diagnosed cancers
[2]. Cervical cancer is the second most commonly diagnosed cancer,
affecting the reproductive system in females throughout the world. It
accounted for some 8% of the total new cancer cases and 7.5% of
the total cancer deaths among women in 2012 [3]. Among the eco-
nomically developed countries, it demonstrates the highest incidence
rates in Central and Eastern Europe.
Since 1977, when zur Hausen published his results, it has been
known that human papillomavirus (HPV) infection is a fundamental
causative factor of cervical cancer [4]. Despite the introduction of
effective vaccination against this infection, it has emerged that it does
not have any therapeutic effect against already-established infections
or in asymptomatic carriers [5]. The therapeutic interventions include
radical surgery, brachytherapy and in most cases platinum-based
chemotherapy or a combination of these [6]. As concerns the thera-
peutic difficulties involved in the treatment regimens, adverse effects
including haematological and gastrointestinal toxicities or the lack of
a significant improvement in survival rate have been reported in con-
nection with cisplatin, in spite of promising drug and/or radiation
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combinations [7]. The need for newer, more potent and better-toler-
ated drugs for the therapy of this special type of cancer has therefore
not declined.
An endogenous metabolite of 17b-estradiol, 2-methoxyestradiol
(2-ME), was earlier one of the most widely investigated steroidal anti-
cancer agents, thanks to its potent antiproliferative activity against
numerous cancer cell lines [reviewed in 8], including cervical cancer
[9–11]. Concomitantly, various analogues of 2-ME have been synthe-
tized and tested on cancer cell lines [reviewed in 12], and certain A-
and/or D-ring-modified 2-ME derivatives have been reported to exhibit
the same or even higher antiproliferative activities (determined most
frequently on breast cancer cell lines) than those of 2-ME. However,
in the vast majority of the cases, the spectrum of investigations
focusing on the mechanisms of action of these potent antiproliferative
compounds has been limited to the determination of their effects on
tubulin polymerization. It has been concluded that the investigated 2-
ME derivatives, increase tubulin depolymerization directly similarly to
2-ME. Until recently, only one research group had published experi-
mental results relating to the mechanism of antiproliferative action of
novel 2-ME analogues in HeLa cells [13]. The three sulphamoylated
analogues investigated induce programmed cell death in HeLa cells
via the extrinsic and intrinsic apoptotic pathways followed by auto-
phagy. Their action on tubulin polymerization was elucidated through
the use of direct, fluorescence-based tubulin polymerization assays
and the microscopic analysis of intracellular microtubules. It was
revealed that, similarly to 2-ME, the sulphamoylated analogues
increase tubulin depolymerization both in a cell-free system and in liv-
ing cells. These effects were also demonstrated in MDA-MB-231
breast cancer cells treated with the sulphamoylated analogues.
The present test compound, D-homoestrone, is an analogue of 2-
ME with structural modifications in its A- and D-rings. This compound
was earlier reported to exert potent antiproliferative activity in human
cervical cancer cells (HeLa), inducing a cell cycle blockade followed
by apoptosis, as demonstrated by morphological markers and cas-
pase 3 activation [14]. In consequence of its selective proliferation-
inhibiting effect and its structural difference relative to the previously
investigated 2-ME analogues, the aim of the present study was to
establish whether the intracellular events induced by D-homoestrone
in HeLa cells are comparable to those in the case of 2-ME or not.
Among others, specific, immune reaction-based flow cytometric
analysis, analysis of the mRNA and protein expression of factors
involved in the G2/M phase transition and in vitro direct tubulin poly-




Normal D-homoestrone (Fig. 1) was synthetized by W€olfling et al. as
described previously [15]. All other chemicals and kits, if otherwise not
specified, were purchased from Sigma-Aldrich Ltd. (Budapest, Hun-
gary).
Cell cultures
The HeLa human cervix epitheloid carcinoma cell line was purchased from
ECACC (European Collection of Cell Cultures, Salisbury, UK). HeLa cells
were grown in DMEM supplemented with 10% heat-inactivated foetal calf
serum, 1% non-essential amino acids and 1% penicillin–streptomycin in
a humidified atmosphere containing 5% CO2 at 37°C. The medium and
supplements were obtained from Life Technologies (Paisley, UK). Cell
counts were determined with a Z1 Coulter Particle Counter (Beckman
Coulter Hungary Ltd., Budapest, Hungary). Cells in the near-confluent
phase of growth were used in all the studies described below.
Antiproliferative (MTT) assay
The growth-inhibitory effects of D-homoestrone were determined on
SiHa (an HPV-16-positive cervical cancer cell line) and C33A (an HPV-
negative cervical cancer cell line) cells to demonstrate the selectivity of
its antiproliferative effect towards HPV-18-positive cervical cancer cells.
Experiments were carried out in the same way as in the previously
described investigations on HeLa cells [14]. Briefly, all cell types were
seeded into 96-well plates at a density of 5000 cells/well and incubated
with increasing concentrations (0.1–30 lM) of D-homoestrone at 37°C
under cell culturing conditions. After a 72-hrs incubation, cells were
treated with 5.0 mg/ml MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-
tetrazolium bromide) solution for 4 hrs, the precipitated formazan crys-
tals were dissolved in dimethyl sulphoxide, and the absorbance was
read at 545 nm with a microplate reader; wells with untreated cells
were utilized as controls [16]. Sigmoidal dose–response curves were fit-
ted to the measured points, and the IC50 values were calculated by
means of GraphPad Prism 4 (GraphPad Software, San Diego, CA, USA).
Determination of in situ caspase-8 activity
To analyse the effects of D-homoestrone on the activity of caspase-8, the
enzyme involved in the extrinsic apoptotic pathway, a commercially avail-
able colourimetric assay was performed. Briefly, near-confluent HeLa
cells were seeded in tissue culture flasks (106 and 107 cells/flask for
untreated control and treated samples, respectively) and grown overnight
under standard cell culturing conditions. The cells were then incubated
with increasing concentrations (1.25, 2.5 and 5.0 lM) of the test com-
pound for 72 hrs. Meanwhile, the medium of the untreated control cells
was replaced. After incubation, the cells were counted, centrifuged and
washed with PBS. Aliquots containing 107 cells were suspended in 100 ll
of kit lysis buffer and incubated on ice for 20 min. The lysed cells were
subsequently centrifuged and the supernatants were used for the mea-
A B
Fig. 1 Chemical structures of D-homoestrone (A) and 2-methoxyestradiol
(B).
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surement. In accordance with the manufacturer’s protocol, 10 ll portions
of treated and untreated supernatants were incubated with 10 ll of ace-
tyl-Ile-Glu-Thr-Asp p-nitroaniline, a selective caspase-8 substrate, in a
final volume of 100 ll in assay buffer. As a control experiment, 10 ll of
each sample was incubated with 10 ll of caspase-8 substrate and 2.0 ll
of acetyl-Ile-Glu-Thr-Asp-aldehyde, a selective caspase-8 inhibitor, in a
final volume of 100 ll in assay buffer. Each sample was prepared in five
parallels. A standard solution of caspase-8 was used as positive control
in parallel with inhibitor-treated samples. After an overnight incubation at
37°C, the absorbance of the p-nitroaniline released was measured at
405 nm. Comparison of the absorbance of p-nitroaniline from the treated
sample with that of an untreated control sample allowed determination of
the fold increase in caspase-8 activity.
Determination of in situ caspase-9 activity
To analyse the effects of D-homoestrone on the proteolytic activity of
caspase-9, the enzyme involved in the intrinsic apoptotic pathway, a
commercially available colourimetric assay (Invitrogen, Carlsbad, CA,
USA) was performed. The preparation of the cells before cell lysis was
identical with the method described for the determination of in situ cas-
pase-8 activity. Aliquots containing 3 9 106 cells were then suspended
in 50 ll of kit lysis buffer and incubated on ice for 10 min. The lysed
cells were subsequently centrifuged and the supernatants were used for
the measurement. In accordance with the manufacturer’s protocol,
50 ll portions of treated and untreated supernatants were incubated
with 5.0 ll of Leu-Glu-His-Asp-p-nitroaniline, a selective caspase-9 sub-
strate, in a final volume of 105 ll in reaction buffer containing 10 mM
dithiothreitol. Each sample was prepared in five parallels. After an over-
night incubation at 37°C, the absorbance of the p-nitroaniline released
was measured at 405 nm. Comparison of the absorbance of p-nitroani-
line from the treated sample with that of an untreated control sample
allowed determination of the fold increase in caspase-9 activity.
Analysis of the G2/M phase transition by flow
cytometry
For a quantitative characterization of the action of the test compound
on the G2/M phase transition in HeLa cells, immunocytochemical flow
cytometric analysis was performed. HeLa cells (105/well) were seeded
in 6-well plates and allowed to proliferate for 48 hrs. On the 3rd experi-
mental day, the cells were treated with 20 lM D-homoestrone for
24 hrs, i.e. the concentration and incubation period used in the previ-
ously reported cell cycle analysis [14]. With regard to previous results,
2-ME was administered at 5.0 lM for 24 hrs to demonstrate its direct
effect on the G2/M phase transition [10]. 5.0 nM paclitaxel was applied
as a positive control for 20 hrs [17] to demonstrate the adaptability of
the experimental method. The medium of the control cells was concom-
itantly replaced. After incubation, the cells were counted, washed with
PBS, centrifuged and resuspended in the 19 wash buffer of the com-
mercially available flow cytometric kit (Millipore Co., Billerica, MA,
USA). Samples were fixed by adding fixation buffer and incubated for
20 min. at 4°C. After removal of the supernatant by centrifugation, cells
were resuspended in ice-cold 19 permeabilization buffer and incubated
for 5 min. at 4°C. The supernatant was removed by centrifugation and
the samples were washed once by adding 19 assay buffer. The cells
were first stained with anti-phospho-histone H3 (Ser10) antibody
directly conjugated to Alexa Fluor 488 for 1 hr at 4°C in the dark. After
an additional washing step with 19 assay buffer, the cells were incu-
bated with freshly-prepared propidium iodide/RNase solution for
30 min. at room temperature in the dark. Samples were analysed on a
Partec CyFlow instrument (Partec GmbH, M€unster, Germany). In each
analysis, 20,000 events were recorded, and the percentage of the cells
in the M phase was determined by using Flowing Software 2.5 (Cell
Imaging Core, Turku Centre for Biotechnology, Turku, Finland). The
fraction stained with anti-phospho-histone H3 (Ser10) antibody was
regarded as the cell population in the M phase [18]. Each sample was
prepared in three parallels and the experiment was repeated twice.
RT-PCR studies
The effects of the tested compound on the mRNA expression pattern of
cyclin-dependent kinase 1 (Cdk1), together with cyclin B1 and B2, and its
regulator factors Cdc25B and Cdc25C, which play a crucial role in the
transition from the G2 to the M phase of the cell cycle, were determined
by RT-PCR in HeLa cells. After a 48-hrs incubation period, the medium
containing the various test compounds was discarded and the total RNA
was isolated from the cells (5 9 105) through use of the TRIzol Reagent
in accordance with the instructions of the manufacturer (Life Technolo-
gies) [19]. The pellet was resuspended in 100 ll of DNase- and RNase-
free distilled water. The RNA concentrations of the samples were deter-
mined from their absorbances at 260 nm. The RNA (0.5 lg) was mixed
with DNase- and RNase-free distilled water and 20 lM oligo(dT)15 (Pro-
mega, Madison, WI, USA), in a final reaction volume of 10 ll, and was
incubated at 70°C for 5 min. After the mixture had been cooled to 4°C,
20 U of RNase inhibitor (FermentasTM, Thermo Fisher Scientific Inc., Wal-
tham, MA, USA), 20 U of MMLV reverse transcriptase (Promega),
200 lM dNTP (Life Technologies) in 50 mM Tris-HCl, pH 8.3, 75 mM KCl
and 5 mM MgCl2 in a final reaction volume of 10 ll were added. The mix-
ture was incubated at 37°C for 60 min. The PCR was carried out with 5 ll
of cDNA, 12.5 ll of AccuStart GelTrack PCR SuperMix (Quanta Bioscienc-
es Inc., Gaithersburg, MD, USA), 2 ll of 20 pM sense and the antisense
primer of Cdk1, cyclin B1, cyclin B2, Cdc25B, Cdc25C and 3.5 ll of
DNase- and RNase-free distilled water. The primer sequences used to
amplify Cdk1, cyclin B1 and B2, Cdc25B and Cdc25C were described by
Shi et al. [20], Bellanger et al. [21], Takemasa et al. [22] and Lau et al.
[23], respectively. Human glyceraldehyde 3-phosphate dehydrogenase
primers were used as internal control in all samples (Table S1) [24]. The
PCR was performed with an ESCO SWIFT MAXI thermal cycler (Esco
Technologies Inc, Philadelphia, PA, USA) and the products were separated
on 2% agarose gels, stained with ethidium bromide and photographed
under a UV transilluminator. Each sample was prepared in three parallels
and the experiments were repeated twice. Semiquantitative analysis was
performed by densitometric scanning of the gel with Kodak IMAGE STA-
TION 2000R (Eastman Kodak Co., Rochester, NY, USA).
Western blotting studies
To investigate the action of D-homoestrone on the function of CDK1,
phosphorylated and total stathmin protein expression was determined by
western blot analysis. HeLa cells were harvested in 60-mm dishes at a
density of 2 9 105 cells/ml and treated with D-homoestrone for 48 hrs.
Whole-cell extracts were prepared by washing the cells with PBS and sus-
pending them in lysis buffer (50 mM Tris, 5 mM EDTA, 150 mM NaCl,
1%NP-40, 0.5%deoxycholic acid, 1 mMsodiumorthovanadate, 100 lg/ml
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phenylmethanesulfonylfluoride (PMSF) and protease inhibitors) [25].
10 lg of protein per well was subjected to electrophoresis on 4–12% Nu-
PAGE Bis–Tris Gel in XCell SureLock Mini-Cell Units (Invitrogen). Proteins
were transferred from gels to nitrocellulose membranes though use of the
iBlot Gel Transfer System (Invitrogen). Antibody binding was detected
with the WesternBreeze Chemiluminescent Western blot immunodetection
kit (Invitrogen). The blots were incubated on a shaker with stathmin
(Op18: rabbit polyclonal antibody raised against amino acids 1-149 repre-
senting full-length human protein), phosphorylated stathmin (p-Op18:
rabbit polyclonal antibody raised against a short amino acid sequence
containing phosphorylated Ser25 of human protein) and b-actin poly-
clonal antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA) 1:200 in
the blocking buffer. Each sample was prepared in three parallels and the
experiments were repeated twice. Semiquantitative analysis was per-
formed by densitometric scanning of the blot with the Kodak IMAGE STA-
TION 2000R (Eastman Kodak Co.).
Tubulin polymerization assay
The direct effect of D-homoestrone on tubulin polymerization was tested
with the Tubulin Polymerization Assay Kit (Cytoskeleton Inc., Denver, CO,
USA) according to the manufacturer’s recommendations. Briefly, 10 ll of
250 or 500 lM test compound solution was subjected to a pre-warmed
(37°C), UV-transparent microplate; 10 ll of 10 lM paclitaxel and 10 ll of
general tubulin buffer served as positive and untreated control, respec-
tively. 100 ll of 3.0 mg/ml tubulin in 80 mM PIPES pH 6.9, 2 mM MgCl2,
0.5 mM ethylene glycol tetraacetic acid (EGTA), 1 mM guanosine tripho-
sphate (GTP), 10.2% glycerol was added to each sample, and the micro-
plate was immediately placed into a pre-warmed (37°C) UV-
spectrophotometer (SpectoStarNano, BMG Labtech, Ortenberg, Germany)
to start the recording of the reaction. A 60-min. kinetic measurement pro-
tocol was applied for determination of the absorbance of the reaction
solutions at 1-min. intervals at 340 nm. For evaluation of the experimental
data, a tubulin polymerization curve was created by plotting optical den-
sity against time, and the maximum reaction rate (Vmax; Dabsorbance/
min.) was calculated. The differences between the absorbances deter-
mined at two consecutive measuring timepoints were calculated, and the
highest difference was taken as the Vmax value of the tested compound in
the tubulin polymerization reaction. Each sample was prepared in two par-
allels and the measurements were repeated twice.
Statistical analysis
For statistical evaluation, the experimental data were in all cases analy-
sed by one-way ANOVA with the Neumann–Keuls post test, using Graph-
Pad Prism version 4.01 for Windows (GraphPad Software, San Diego,
CA, USA).
Results
Selective antiproliferative effect of
D-homoestrone on HeLa cells
The proliferation-inhibiting effect of D-homoestrone was demon-
strated not only on the HeLa (HPV-18-positive) cervical cancer cell
line [14], but also on two other cervical cancer cell lines: SiHa (HPV-
16-positive) and C33A (HPV-negative). D-Homoestrone did not give
rise to effective inhibition of the proliferation of either SiHa nor C33A
cells. The calculated IC50 values were from three separate experi-
ments 30.7  0.4 lM for SiHa and 32.4  6.3 lM for C33A cells.
The calculated IC50 value of D-homoestrone on HeLa cells was previ-
ously reported to be 5.5 lM [14].
Involvement of the intrinsic apoptotic pathway in
programmed cell death induced by
D-homoestrone
To obtain novel and conclusive information about the mechanism of
action of apoptosis induction triggered by D-homoestrone, the activi-
ties of caspase-8 and -9 on HeLa cells were determined after expo-
sure to 1.25, 2.5 or 5.0 lM of the test compound for 72 hrs. D-
Homoestrone induced a concentration-dependent and significant
increase in in situ caspase-9 activity on HeLa cells relative to the
untreated control samples, indicating the participation of the intrinsic
pathway in the development of apoptotic cell death (Fig. 2A). How-
ever, no significant alteration in caspase-8 activity was detected in the
D-homoestrone-treated HeLa cells as compared with the untreated
control samples (Fig. 2B).
D-Homoestrone blocks the cell cycle in the G2
phase
D-Homoestrone has been revealed by flow cytometric analysis to
increase the ratio of cells in the G2/M phase significantly [14]. To
establish its exact mechanism of action, immunocytochemical flow
cytometric analysis was performed. The test compound significantly
decreased the ratio of phosphorylated histone H3 protein relative to
the untreated control HeLa cells (Fig. 3), indicating the reduction of
the cells in the M phase. Paclitaxel, a widely known mitotic blocking
agent [26], was used as positive control. It increased the ratio of
phosphorylated histone H3 protein significantly as compared with the
untreated control HeLa cells (Fig. 3). Moreover, after the treatment of
HeLa cells with 2-ME for 24 hrs, the proportion of phosphorylated
histone H3 protein was also significantly increased relative to the
untreated control cells (Fig. 3).
Inhibition of regulatory proteins of the G2/M
phase transition at the mRNA level
The G2/M transition is known to be a rigorously regulated process
during the cell cycle [27]. If the function of the regulatory pathway is
affected, cells may not enter the M phase and accumulate in the G2
phase. Although the mRNA expression of the executioner enzyme
(Cdk1) demonstrated a non-significant alteration in HeLa cells incu-
bated with D-homoestrone for 48 hrs, those of the activating part of
the Cdk1-cyclin B complex and its direct upstream regulatory factors
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(e.g. Cdc25B and Cdc25C) were significantly reduced relative to the
untreated control cells. However, the mRNA expression of cyclin B2
and Cdc25C was reduced significantly in the presence of 10 lM D-ho-
moestrone alone (Fig. 4).
Functional blockade of the Cdk1-cyclin B
complex
In response to a 48-hrs incubation with D-homoestrone, the protein
expression of phospho-stathmin, a microtubule destabilizing protein
phosphorylated and therefore inactivated by Cdk1, significantly
decreased in comparison with the untreated control cells (Fig. 5A).
However, the total protein expression of stathmin did not display a
significant alteration as compared with the untreated control cells
(Fig. 5B).
D-Homoestrone does not elicit a direct effect on
tubulin polymerization
2-ME and other steroidal antiproliferative agents were earlier reported
to affect the tubulin-microtubules system [28, 29], and the effect of
D-homoes trone on tubulin polymerization was therefore also deter-
mined. D-Homoestrone applied in two different concentrations (250
and 500 lM) did not significantly alter the maximum rate of tubulin
A
B
Fig. 2 In situ measurement of caspase-9 (A) and -8 (B) activities in
HeLa cells after treatment with D-homoestrone for 72 hrs. The activities
of caspase-9 and -8 in D-homoestrone-treated samples are expressed
as ratios relative to the activities of caspase-9 or -8 in the control
(untreated) samples. Data are means  SEM, n = 5. ns indicates
P > 0.05, and * indicates P < 0.05 as compared with the untreated
control samples.
Fig. 3 Effects of 20 lM D-homoestrone and 5.0 lM 2-ME on the
expression of p-histone H3 protein in HeLa cells after incubation for
24 hrs, determined by flow cytometric analysis. Results are mean val-
ues  SEM of the data on three separate measurements. * indicates
P < 0.05, and *** indicates P < 0.001 as compared with the untreated
control cells. PAC denotes 5.0 nM paclitaxel and 2-ME denotes 5.0 lM
2-methoxyestradiol.
Fig. 4 Effects of 5.0 lM (open bars) and 10 lM (grey bars) D-homoe-
strone on the mRNA expression of regulating factors participating in the
G2/M transition in HeLa cells after incubation for 48 hrs, determined by
reverse-transcription PCR. Results are mean values  SEM of the data
from two separate measurements, n = 6. * indicates P < 0.05 as com-
pared with the untreated control samples (dashed line at 100%). Non-
significant changes are not indicated. Cdk1 denotes cyclin-dependent
kinase 1.
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polymerization relative to the untreated control samples in an in vitro
1-hr kinetic assay (Fig. 6A). In contrast, the positive control paclitaxel
evoked a nearly threefold increase in Vmax (Fig. 6B).
Discussion
There have been numerous investigations of the antiproliferative
mechanism of action of 2-ME, the first A-ring-modified estradiol
derivative with promising anticancer activity. In view of the chemical
similarity of the structures, the cancer cell proliferation-inhibiting
mechanism of action of 2-ME might be regarded as a common mode
of pharmacological action for all related antiproliferative estradiol
derivatives. However, the present paper provides convincing data of
an alternative mechanism of action of D-homoestrone, a 2-ME ana-
logue with D-ring expansion. D-Homoestrone was earlier shown to
exert a pronounced antiproliferative effect on HeLa cells by inducing
apoptosis, preceded by cell cycle blockade at the G2/M phase [14].
Our research into its detailed mechanism of anticancer action has
revealed some intriguing differences from that in the case of 2-ME.
Antiproliferative assays have been performed with D-homoestrone
on cervical cancer cell lines with various pathological backgrounds
(HPV-16-positive SiHa and HPV-negative C33A cell lines) compared
to HPV-18-positive HeLa cells. The present and previous results
reveal that the anticancer effect of D-homoestrone is selective for
HeLa cells. Although the expressions of the oncoproteins E6 and E7
are detected in both HPV-positive cervical cell lines, which deregulate
fundamental cellular events such as apoptosis, cell cycle, DNA repair,
senescence and differentiation [reviewed in 30], a slight difference in
the apoptotic machinery of these cell lines can be observed. Are-
chaga-Ocampo et al. [31] reported different expression profiles of
caspases in different HPV-positive cervical cell lines. In HeLa cells
(HPV-18+), caspase-3 and -6 displayed low levels of expression,
whereas caspase-7, -8 and -9 were expressed at high levels. In
contrast, most of the caspases were highly expressed in SiHa cells
(HPV-16+), the exception was caspase-8. This difference might be a
possible explanation of the selective susceptibility of HeLa cells to
D-homoestrone.
2-Methoxyestradiol has been reported to induce the process of
programmed cell death in numerous cancer cell lines, including
HeLa(S3) cells, as demonstrated by flow cytometry, fluorescent
microscopy and DNA fragmentation data [10]. During the investiga-
tion of the mechanism of apoptosis, other research groups reported
that 2-ME is able to activate both the intrinsic [11] and the extrinsic
[32] apoptotic pathway in HeLa cells. The present results on cas-
pase-8 and -9 activity allow the conclusion that the previously dem-
onstrated apoptosis-inducing effect of D-homoestrone develops only
through the activation of the intrinsic pathway, since the activity of




Fig. 6 A representative kinetic curve of the
effects of 250 lM D-homoestrone and
10 lM paclitaxel on tubulin polymerization
(A). Direct effects of 250 and 500 lM D-
homoestrone and 10 lM paclitaxel on the
maximum rate of tubulin polymerization
determined by an in vitro kinetic assay
(B). Results are mean values  SEM of
the data from two separate measure-
ments, n = 4. ns indicates P > 0.05 and
*** indicates P < 0.001 as compared
with the untreated control samples.
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Earlier cell cycle analyses on various cancer cell lines (including
HeLa cells) proved that the proportion of cells in the G2/M phase
increased significantly on exposure to 2-ME [10, 33–35]. Similarly,
5.0 lM D-homoestrone evoked a G2/M phase blockade of HeLa
cells [14]. After Li et al. [10] had established that the G2/M phase
arrest induced by 2-ME was mainly due to the inhibition of mitosis
at the metaphase, the question arose of whether the cell cycle
blockade induced by D-homoestrone develops in the G2 or the M
phase. It was earlier reported that an important detectable ‘label’
on the chromosomes indicates to the cell that duplicated chromo-
somes are ready for segregation. The amount of this molecule,
Ser10 phosphorylated histone H3, reaches its maximum in the
metaphase [36]. Moreover, the presence of phosphorylated histone
H3 is a prerequisite for chromatin condensation, which is regarded
as a sign of the onset of the prophase. In our present investigation,
the analysis of the presence of phosphorylated histone H3 on
Ser10 revealed that the proportion of D-homoestrone-treated HeLa
cells containing this form of the protein was decreased dramatically
as compared with the control cells, suggesting that these cells are
neither able to arrive at the metaphase of cell cycle nor to demon-
strate the initiation of the first step of mitosis. Additionally, 2-ME
significantly increased the proportion of phosphorylated histone H3
as protein compared with that in untreated control samples, indi-
cating an increase in the HeLa cells in the M phase. This result is
in good agreement with the recently published data on the cell
cycle blockade induced by 2-ME. In morphological assays, 2-ME-
induced, abnormal spindle formation was observed in the meta-
phase in HeLa(S3) cells [10]. Furthermore, Choi and Zhu [35]
reported that 2-ME selectively induced a mitotic prometaphase
arrest due to its inhibitory effect on microtubule formation, fol-
lowed by activation of the cyclin B1-CDK1 complex, mediated in
part by c-Jun N-terminal kinase (JNK) and mitotic arrest deficient 2
(MAD2) proteins. These experimental findings allow the conclusion
that 2-ME exerts a cell cycle blockade at the beginning of mitosis
and not in the G2 phase. This difference between the effects of 2-
ME and D-homoestrone at this step of the cell proliferation process
is a crucial one.
The cell cycle is a strictly regulated process which ensures the
development of two completely identical and viable cells. It is
divided into specific phases according to unique intracellular
events, and the transition from one phase to the following one is
governed by cascade mechanisms involving various regulatory pro-
teins (e.g. phosphatases, kinases, etc.). The main executor protein
of the G2/M phase transition is Cdk1, the functional activity of
which is strongly dependent on the expression of cyclin B proteins
[27]. During physiological functioning, this complex phosphorylates
the proteins responsible for mitotic entry and progression. The
effects of 2-ME on Cdk1 expression and activity and on cyclin B1
expression have been widely investigated in numerous cancer cell
lines, but not in HeLa cells. The opposite actions of 2-ME on Cdk1
and cyclin B1 expression have been demonstrated, depending on
the cell type investigated. Gong et al. [34] observed an inhibitory
effect of 2-ME on Cdk1-cyclin B1 activity, followed by a cell cycle
arrest at G2/M in RL95-2 human endometrial cells. Two possible
molecular mechanisms have been proposed to explain the cell cycle
blockade; the direct activation of p53 at Ser15, and the indirect
activation of p53 at Ser20 via the induction of checkpoint kinase 1.
In both cases, upregulation of the downstream p21 results in a
A
B
Fig. 5 Effects of 2.5 and 5.0 lM D-homoestrone on the expression of
phosphorylated (A) and total (B) stathmin protein in HeLa cells after
incubation for 48 hrs, determined by western blot analysis. Results are
mean values  SEM of the data from two separate measurements,
n = 6. ns indicates P > 0.05, * indicates P < 0.05 and ** indicates
P < 0.01 as compared with the untreated control cells. The b-actin
probe was used as internal control. Panels below are representative
membrane pictures.
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decreased activity of Cdk1-cyclin B1. Similarly, a decrease in the
expression of Cdk1 and cyclin B1 protein was demonstrated in
MCF-7 cells as a result of 2-ME treatment [37]. However, two other
research groups reported that 2-ME treatment leads to an
increased level of Cdk1 and cyclin B1 protein or only of cyclin B1
protein in MCF-7 cells [33, 35]. However, it was finally concluded
that the observed effect may be connected with mitotic progression
and not with mitotic entry. In spite of the limitations of the applied
PCR technique, D-homoestrone with a selective antiproliferative
effect on HeLa cells proved to decrease the mRNA expressions of
cyclin B1 and B2 significantly, but not to affect that of Cdk1, sug-
gesting a reduced functional activity of the complex during the
prophase of mitotic entry. The reduced functional activity of the
Cdk1-cyclin B complex was confirmed by investigation of the phos-
phorylated form and the total stathmin expression. Stathmin is one
of the several targets of Cdk1; the phosphorylated form of this pro-
tein becomes inactive, allowing the formation of microtubules from
tubulin heterodimers sequestered earlier by active stathmin, or the
inhibition of its microtubule catastrophe-promoting activity when
cells enter mitosis (i.e. in the prophase) [38]. Our results revealed
a significantly decreased protein expression of phosphorylated (and
therefore inactivated) stathmin after a 48-hrs D-homoestrone treat-
ment, whereas the total stathim expression did not exhibit a
marked change. This suggests that D-homoestrone induces the
expression of active stathmin, resulting in dysregulation of the
dynamic instability of the tubulin-microtubule system.
On the other hand, there is an upstream regulatory system which
is able to influence the activity of the Cdk1-cyclin B complex. The
members of this system include Cdc25B and Cdc25C phosphatases,
which activate Cdk1 by dephosphorylating Tyr15 and Thr14 [39].
Moreover, Cdc25A and B are known to be overexpressed in a diverse
array of human cancers, suggesting an important role of the Cdc25s
in the development of uncontrolled cancer cell division [40]. In our
experiments, the Cdc25B mRNA expression was demonstrated to be
reduced significantly after a 48-hr treatment with 5.0 or 10 lM D-ho-
moestrone, suggesting decreasing enzymatic activity. However, the
change in the mRNA level of Cdc25C, the other phosphatase partici-
pating in the control of entry into mitosis, decreased significantly only
after treatment with the higher dose of D-homoestrone. These find-
ings are consistent with previous results indicating that Cdc25B is the
initial trigger of mitotic onset and its expression starts slightly earlier
than that of Cdc25C [41]. Until recently, the effects of 2-ME on the
activity and/or expression of Cdc25 phosphatases had been only
poorly investigated. In a cell-free experiment, it inhibited the activity
of Cdc25B and C directly [42], and it was also shown to alter the
expression profile of the active or inactive form of Cdc25C in different
cancer cell lines [35, 43, 44].
Our investigation aimed at an understanding of the antiprolifera-
tive mechanism of action of D-homoestrone, additionally demon-
strated its direct effect on tubulin polymerization. 2-ME has been
reported to inhibit tubulin polymerization in consequence of its inter-
action with the colchicine-binding site of b-tubulin [12]. This effect
seems to develop during the initial steps of mitosis, which it may
allow the conclusion that 2-ME causes the cell cycle arrest at the M
phase. In contrast, D-homoestrone did not exhibit any significant
action on tubulin polymerization relative to non-treated control sam-
ples in an in vitro, cell-free experimental setting. This difference is
another significant factor in the comparison of the mechanism of anti-
proliferative action of D-homoestrone with that of 2-ME.
Overall, our current results suggest that D-homoestrone causes a
functional loss of the Cdk1-cyclin B complex, resulting in failure of
the G2/M transition in HeLa cells. In contrast with 2-ME, this mole-
cule does not interfere directly with the dynamic equilibrium of tubu-
lin-microtubule system, but because of the inhibited inactivation of
stathmin it indirectly disturbs the microtubule formation at the begin-
ning of mitotic entry. Finally, our additional experimental data indicate
that D-homoestrone arrests the cell cycle progression immediately
before the HeLa cells start to enter mitosis; this is followed by the
induction of programmed cell death which, unlike the case with 2-ME,
is executed solely via the intrinsic apoptotic pathway. We consider
that this alternative mechanism of anticancer action of D-homoestrone
in HeLa cells is a promising novel feature in the search for lead com-
pounds against human cervical carcinoma.
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